Skip to main content

Table 3 Type 2 diabetes risk upon co-exposure stratified by CumCRP thresholds (1, 3 mg/L) and CumAIP (median)

From: Temporal relationship between atherogenic dyslipidemia and inflammation and their joint cumulative effect on type 2 diabetes onset: a longitudinal cohort study

 

Combination of CumCRP and CumAIP, HRs (95% CIs)

G1

G2

G3

G4

G5

G6

Event/total

429/8086

789/8585

489/5009

709/5932

1612/9966

1090/5789

Incidence ratea

7.27

12.82

13.80

17.17

23.59

27.84

 Model (unadjusted)

Reference

1.77 (1.58, 1.99)

1.90 (1.67, 2.16)

2.35 (2.08, 2.65)

3.25 (2.92, 3.61)

3.84 (3.43, 4.29)

 Model 1

Reference

1.54 (1.37, 1.73)

1.47 (1.29, 1.68)

1.97 (1.75, 2.23)

2.41 (2.16, 2.69)

2.55 (2.27, 2.86)

 Model 2

Reference

1.49 (1.32, 1.68)

1.52 (1.33, 1.73)

1.75 (1.55, 1.98)

2.12 (1.90, 2.36)

2.38 (2.11, 2.67)

 Model 3

Reference

1.58 (1.40, 1.78)

1.44 (1.27, 1.65)

1.64 (1.45, 1.86)

1.87 (1.68, 2.09)

2.04 (1.81, 2.30)

P for interaction: CumAIP median × logCumCRP = 0.0113; CumAIP median × CumCRP cut-points (1, 3 mg/L) = 0.0369

  1. G1: CumAIP < − 0.0701 and CumCRP < 1 mg/L; G2: CumAIP < − 0.0701 and 1 ≤ CumCRP < 3 mg/L; G3: CumAIP < − 0.0701 and CumCRP ≥ 3 mg/L; G4: CumAIP ≥ − 0.0701 and CumCRP < 1 mg/L; G5: CumAIP ≥ − 0.0701 and 1 ≤ CumCRP < 3 mg/L; G6: CumAIP ≥ − 0.0701 and CumCRP ≥ 3 mg/L
  2. Model 1: adjusted for age, sex, education, smoking, drinking status, physical activities, family history of diabetes, and BMI
  3. Model 2: model 1 + FBG, TC, blood pressure (categorical), eGFR (categorical), antihypertensives, and lipid-lowering drugs
  4. Model 3: model 2 + fatty liver (categorical)
  5. Abbreviations: CumAIP, cumulative atherogenic index of plasma; CumCRP, cumulative high-sensitivity C-reactive protein; HR, hazard ratio; BMI, body mass index; FBG, fasting blood glucose; TC, total cholesterol; eGFR, estimated glomerular filtration rate; INTm, multiplicative interaction
  6. aThe incidence rate is per 1000 person-years